Activity Overview
This video-based program is designed for health care professionals to explore the impact of atopic dermatitis (AD) on young children and their caregivers and to review recent guidelines on the use of topical therapies in these patients. A parent of a young child with AD shares their experience managing her symptoms and provides behind-the-scenes insights for dermatologists and other clinicians. In addition, a pair of pediatric dermatologists discuss key takeaways on individualizing therapy for patients with pediatric AD.
Target Audience
This educational activity is directed toward pediatric dermatologists, pediatricians, nurse practitioners, physician assistants, and other health care providers who treat pediatric AD.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the substantial negative impact of pediatric AD on the QoL of both the child and their family/caregiver
- Evaluate safety and efficacy of approved novel non-steroidal ATTs for AD in children aged 2 to 5 years
- Develop personalized treatment plans incorporating ATTs to manage AD in children aged 2 to 5 years based on patient-specific needs and shared goals of therapy
Linda Stein Gold, MD
Director of Dermatology Clinical Research, Division Head of Dermatology, Henry Ford Health System
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, Alumis, Amgen, Arcutis, Aruka Bio, Bristol Myers Squibb, Galderma, Johnson & Johnson, Kymera, LEO Pharma, Lilly, Organon, Pfizer, Regeneron, Sanofi; Speakers Bureau: AbbVie, Amgen, Arcutis, Galderma, Johnson & Johson, LEO Pharma, Lilly, Organon, Pfizer, Regeneron, Sanofi; Grant/Research Funding: AbbVie, Alumis, Amgen, Arcutis, Aruka Bio, Bristol Myers Squibb, Galderma, Johnson & Johnson, Kymera, LEO Pharma, Lilly, Organon, Pfizer, Regeneron, Sanofi
Elizabeth (Lisa) A. Swanson, MD
Pediatric Dermatologist, Ada West Dermatology
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Almirall, Alphyn Biologics, Arcutis, Boehringer Ingelheim, Castle Biosciences, Chiesi, Eli Lilly, Galderma, Incyte Corporation, Johnson & Johnson, LEO Pharma, Organon, Pelthos, Pfizer, Regeneron, Sanofi, Verrica
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here